Aucatzyl is the first CAR-T cell therapy approved by the FDA with no requirement for a risk evaluation mitigation strategy ...

The expression of MICA/B cell-surface proteins is induced by cellular stress ... or other attributes to warrant further ...

Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease HLHS has achieved more than 80% enrollmentPositive Type C ...

CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and ...

(Created with Biorender.com) ArcZ, small RNA that regulates ArcA/B regulon; DinB, DNA polymerase IV named for its DNA Damage, ...

Good day and welcome to the Vertex Pharmaceuticals third-quarter 2024 earnings call. (Operator Instructions) Please note this event is being recorded. I would now like to turn the conference over to ...

In the healthcare sector, companies often work towards crucial events or milestones that can drive significant changes in a ...

Q3 2024 Earnings Call Transcript November 5, 2024 Operator: Good morning, everyone, and welcome to the Cellectis Third ...

Q3 2024 Earnings Call Transcript November 8, 2024 Y-mAbs Therapeutics, Inc. reports earnings inline with expectations.

This regulatory milestone is the second time BTD has been granted ... including up to 20 times higher risk of developing B-cell lymphomas when compared to the general population. Patients with high ...